Aliases & Classifications for Cardiac Arrhythmia

MalaCards integrated aliases for Cardiac Arrhythmia:

Name: Cardiac Arrhythmia 57 29 6
Adverse Event Associated with Cardiac Arrhythmia 73
Premature Cardiac Complex 73
Extrasystoles 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
cardiac arrhythmia:
Inheritance autosomal dominant inheritance
Mortality/Aging sudden death


External Ids:

OMIM 57 115000
MedGen 42 C0003811
SNOMED-CT via HPO 69 263681008 88425004 26636000

Summaries for Cardiac Arrhythmia

MalaCards based summary : Cardiac Arrhythmia, also known as adverse event associated with cardiac arrhythmia, is related to cardiac conduction defect and long qt syndrome 13, and has symptoms including pulsus trigeminus and bigeminal pulse. An important gene associated with Cardiac Arrhythmia is TANGO2 (Transport And Golgi Organization 2 Homolog), and among its related pathways/superpathways are Circadian entrainment and Aldosterone synthesis and secretion. The drugs Guaifenesin and Methadone have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are abnormality of the nervous system and polymorphic and polytopic ventricular extrasystoles

Description from OMIM: 115000

Related Diseases for Cardiac Arrhythmia

Diseases related to Cardiac Arrhythmia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
# Related Disease Score Top Affiliating Genes
1 cardiac conduction defect 31.5 KCNH2 KCNQ1 RYR2 SCN5A
2 long qt syndrome 13 31.5 KCNH2 KCNQ1 SCN5A
3 arrhythmogenic right ventricular dysplasia, familial, 8 31.5 JUP RYR2
4 long qt syndrome 9 31.4 KCNJ2 SCN5A
5 brugada syndrome 1 31.1 KCNH2 SCN5A
6 familial short qt syndrome 30.3 KCNH2 KCNJ2 KCNQ1
7 sick sinus syndrome 30.3 RANGRF SCN5A
8 andersen cardiodysrhythmic periodic paralysis 30.1 KCNE2 KCNH2 KCNJ2 KCNQ1 SCN5A
9 cardiac arrest 30.0 KCNQ1 RYR2 SCN5A
10 sudden infant death syndrome 29.7 KCNH2 KCNQ1 RYR2 SCN5A
11 long qt syndrome 12 29.5 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
12 syncope 29.4 KCNH2 KCNJ2 KCNQ1 SCN5A
13 long qt syndrome 3 29.1 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
14 hypokalemic periodic paralysis, type 1 28.5 CACNA1C KCNJ2
15 heart disease 28.4 KCNE2 KCNH2 KCNJ2 KCNQ1 RYR2 SCN5A
16 ventricular fibrillation, paroxysmal familial, 1 28.2 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1 RYR2
17 long qt syndrome 2 27.7 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
18 long qt syndrome 5 27.7 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
19 long qt syndrome 1 27.1 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
20 long qt syndrome 6 26.6 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
21 brugada syndrome 26.3 ANK2 CACNA1C JUP KCNE1 KCNE2 KCNH2
22 atrial fibrillation 26.2 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
23 long qt syndrome 25.4 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
24 intellectual developmental disorder with cardiac arrhythmia 12.5
25 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 12.4
26 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 12.3
27 cardiac arrhythmia, ankyrin-b-related 12.3
28 muscular dystrophy, limb-girdle, type 2x 11.6
29 ogden syndrome 11.6
30 tango2-related metabolic encephalopathy and arrhythmias 11.2
31 myotonic dystrophy 1 11.1
32 spondylometaphyseal dysplasia, sedaghatian type 11.1
33 carnitine palmitoyltransferase ii deficiency, lethal neonatal 11.0
34 thyrotoxic periodic paralysis 11.0
35 refsum disease, classic 10.8
36 heterotaxy, visceral, 1, x-linked 10.8
37 cardiomyopathy, infantile histiocytoid 10.8
38 hypomagnesemia 1, intestinal 10.8
39 myotonic dystrophy 2 10.8
40 long qt syndrome 11 10.8
41 ventricular fibrillation, paroxysmal familial, 2 10.8
42 glycogen storage disease xv 10.8
43 congenital heart defects, multiple types, 4 10.8
44 chronic atrial and intestinal dysrhythmia 10.8
45 his bundle tachycardia 10.8
46 renal tubular acidosis, distal 10.8
47 uhl anomaly 10.8
48 ventricular extrasystoles with syncopal episodes - perodactyly - robin sequence 10.8
49 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 10.3 JUP RYR2
50 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 10.3 JUP RYR2

Comorbidity relations with Cardiac Arrhythmia via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Familial Atrial Fibrillation
First-Degree Atrioventricular Block Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Ischemic Heart Disease Mitral Valve Disease
Sinoatrial Node Disease

Graphical network of the top 20 diseases related to Cardiac Arrhythmia:



Diseases related to Cardiac Arrhythmia

Symptoms & Phenotypes for Cardiac Arrhythmia

Symptoms via clinical synopsis from OMIM:

57
Cardiac:
arrhythmia
polymorphic and polytopic ventricular extrasystoles

Misc:
sudden death

Neuro:
syncopal attacks


Clinical features from OMIM:

115000

Human phenotypes related to Cardiac Arrhythmia:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 32 HP:0000707
2 polymorphic and polytopic ventricular extrasystoles 32 HP:0006696

UMLS symptoms related to Cardiac Arrhythmia:


pulsus trigeminus, bigeminal pulse

MGI Mouse Phenotypes related to Cardiac Arrhythmia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.56 CACNA1C GNB5 JUP KCNH2 KCNJ2 KCNQ1
2 muscle MP:0005369 9.23 CACNA1C GNB5 JUP KCNH2 KCNJ2 KCNQ1

Drugs & Therapeutics for Cardiac Arrhythmia

Drugs for Cardiac Arrhythmia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 556)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2
Methadone Approved Phase 4 76-99-3 4095
3
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
4
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 51-43-4 5816
5
Racepinephrine Approved Phase 4,Phase 1,Not Applicable 329-65-7 838
6
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
7
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
8
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable 1951-25-3 2157
9
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-61-7 60961
10
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
11 fluindione Approved, Investigational Phase 4,Phase 3 957-56-2
12
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 23994
13
Dobutamine Approved Phase 4,Phase 3,Not Applicable 34368-04-2 36811
14
Milrinone Approved Phase 4,Phase 2,Not Applicable 78415-72-2 4197
15
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
17
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable 2216-51-5 16666
18
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
19 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 979-32-8
20
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
21
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
22
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 1 35189-28-7 6540478
23
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
24
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 437-38-7 3345
26
Atropine Approved, Vet_approved Phase 4,Phase 2 5908-99-6, 51-55-8 174174
27
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
28
Procainamide Approved Phase 4,Phase 3,Not Applicable 51-06-9 4913
29
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
30
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
31
Morphine Approved, Investigational Phase 4 57-27-2 5288826
32
Ibutilide Approved Phase 4,Phase 2,Not Applicable 122647-32-9, 122647-31-8 60753
33
Magnesium citrate Approved Phase 4,Not Applicable 3344-18-1
34
Magnesium oxide Approved Phase 4,Not Applicable 1309-48-4 14792
35
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
36
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
37
Eplerenone Approved Phase 4,Phase 3 107724-20-9 150310 443872
38
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
39
Diltiazem Approved, Investigational Phase 4,Not Applicable 42399-41-7 39186
40
Metoprolol Approved, Investigational Phase 4,Not Applicable 37350-58-6, 51384-51-1 4171
41
Dopamine Approved Phase 4,Phase 3,Not Applicable 51-61-6, 62-31-7 681
42
Haloperidol Approved Phase 4,Phase 3,Not Applicable 52-86-8 3559
43
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
44
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
45
Metformin Approved Phase 4 657-24-9 14219 4091
46
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
47
Insulin Glargine Approved Phase 4 160337-95-1
48
Insulin Lispro Approved Phase 4 133107-64-9
49
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 9908 54680692
50
Linagliptin Approved Phase 4 668270-12-0 10096344

Interventional clinical trials:

(show top 50) (show all 827)
# Name Status NCT ID Phase Drugs
1 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
2 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4 Methadone;Placebo
3 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
4 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
5 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
6 Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias Completed NCT00702117 Phase 4 flecainide;ajmaline;procainamide
7 Reveal® XT Performance Trial (XPECT) Completed NCT00680927 Phase 4
8 Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics Completed NCT01719978 Phase 4 3.6mL 2% Mepivacaine with 1:100,000 epinephrine;Hyaluronidase;Placebo
9 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
10 Radiation Exposure Reduction in Supraventricular Tachycardia Ablation Completed NCT01132274 Phase 4
11 Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study - Completed NCT00848445 Phase 4
12 ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
13 Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management Completed NCT02335398 Phase 4 Methadone
14 Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Completed NCT01447862 Phase 4 Brinavess (Vernakalant);Corvert (Ibutilide)
15 Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter Completed NCT01448265 Phase 4
16 Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients Completed NCT01085071 Phase 4 Potassium Chloride;Potassium Chloride
17 Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias Completed NCT00765713 Phase 4
18 Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation Completed NCT00247780 Phase 4
19 The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects Completed NCT00994006 Phase 4
20 Atrial Fibrillation and Congestive Heart Failure Trial Completed NCT00597077 Phase 4
21 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit Completed NCT01461733 Phase 4 amiodarone;Placebo
22 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke Completed NCT00924638 Phase 4
23 Steroids in Fulminant Hepatic Failure in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
24 Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation Completed NCT00552084 Phase 4 Fish oil;Placebo
25 Hemodynamic Responses to Tracheal Intubation Direct Laryngoscope and Videolaryngoscope in Elderly Patients Completed NCT02816775 Phase 4
26 Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction Completed NCT01176968 Phase 4 Eplerenone;Placebo
27 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
28 Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter Completed NCT01914926 Phase 4 Metoprolol;Diltiazem
29 ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial Completed NCT01058980 Phase 4
30 Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation Completed NCT03140631 Phase 4 Protamine Sulfate
31 Study of Optimal Replacement of Thyroxine in the Elderly Completed NCT01647750 Phase 4 Levothyroxine;Levothyroxine
32 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
33 Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol Completed NCT01174290 Phase 4 Haloperidol decanoate;Placebo
34 The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac Surgery Completed NCT03054857 Phase 4 Dexmedetomidine;Placebo
35 Restricted Fluid Therapy in Colorectal Surgery Completed NCT03537989 Phase 4 Saline
36 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease Completed NCT00513630 Phase 4 Glipizide;Metformin
37 Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS) Completed NCT01456949 Phase 4
38 CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI Completed NCT00162331 Phase 4 Technetium Tc99m Sestamibi
39 Trial of Different Hypothermia Temperatures in Patients Recovered From Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
40 Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine Completed NCT01091766 Phase 4 intravenous injection of test solution;intravenous injection of test solution;intravenous injection of test solution
41 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) Completed NCT02348723 Phase 4 Warfarin;Dabigatran Etexilate 150mg
42 The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation Completed NCT01438580 Phase 4 Warfarin;aspirin
43 DPP4 Inhibitor in the Hospital Completed NCT01378117 Phase 4 Sitagliptin;glargine;lispro
44 Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy Completed NCT02227550 Phase 4 Vitamin K antagonist;Apixaban
45 Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia Completed NCT00412607 Phase 4
46 ADA Linagliptin in Long Term Care Completed NCT02061969 Phase 4 linagliptin;insulin glargine
47 Linagliptin Inpatient Trial Completed NCT02004366 Phase 4 Linagliptin;Basal Bolus;Linagliptin;Linagliptin + 50% Glargine dose on discharge;Linagliptin + 80% Glargine
48 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
49 Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145) Recruiting NCT03346057 Phase 4 Sugammadex 2 mg/kg;Sugammadex 4 mg/kg;Sugammadex 16 mg/kg;Neostigmine + Glycopyrrolate
50 Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation Recruiting NCT02426944 Phase 4 NOAC

Search NIH Clinical Center for Cardiac Arrhythmia

Genetic Tests for Cardiac Arrhythmia

Genetic tests related to Cardiac Arrhythmia:

# Genetic test Affiliating Genes
1 Cardiac Arrhythmia 29

Anatomical Context for Cardiac Arrhythmia

MalaCards organs/tissues related to Cardiac Arrhythmia:

41
Heart, Kidney, Testes, Brain, Lung, Endothelial, Thyroid

Publications for Cardiac Arrhythmia

Articles related to Cardiac Arrhythmia:

(show top 50) (show all 377)
# Title Authors Year
1
Special Program and Abstract issue of the 14th Annual Congress of the European Cardiac Arrhythmia Society (ECAS). ( 29546583 )
2018
2
Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP). ( 29619247 )
2018
3
Cardiac Arrhythmia Classification by Multi-Layer Perceptron and Convolution Neural Networks. ( 29734666 )
2018
4
Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. ( 29678624 )
2018
5
Amiodarone for the Successful Management of Caowu Poisoning - Induced Cardiac Arrhythmia. ( 29643705 )
2018
6
Status of cardiac arrhythmia services in Africa in 2018: a PASCAR Sudden Cardiac Death Task Force report. ( 29745966 )
2018
7
Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta-analysis. ( 29740922 )
2018
8
Multiclass Classification of Cardiac Arrhythmia Using Improved Feature Selection and SVM Invariants. ( 29692863 )
2018
9
Is exposure to ionising radiation associated with childhood cardiac arrhythmia in the Russian territories contaminated by the Chernobyl fallout? A cross-sectional population-based study. ( 29581199 )
2018
10
Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B-cell lymphoma upon start of R-CHOP. ( 29531724 )
2018
11
Effects of hawthorn ( Crataegus pentagyna) leaf extract on electrophysiologic properties of cardiomyocytes derived from human cardiac arrhythmia-specific induced pluripotent stem cells. ( 29133340 )
2018
12
European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). ( 29905786 )
2018
13
Kcne4 deletion sex-specifically predisposes to cardiac arrhythmia via testosterone-dependent impairment of RISK/SAFE pathway induction in aged mice. ( 29844497 )
2018
14
Autoimmunity and cardiac arrhythmias in endemic pemphigus foliaceus-Association, correlation, or causation? ( 29369789 )
2018
15
Initial experience of catheter ablation for cardiac arrhythmias in children and adolescents at a newly built ablation centre. ( 28832094 )
2018
16
Retrospective multi-phase non-contrast-enhanced magnetic resonance angiography (ROMANCE MRA) for robust angiogram separation in the presence of cardiac arrhythmia. ( 29427402 )
2018
17
Design of a hybrid model for cardiac arrhythmia classification based on Daubechies wavelet transform. ( 29877638 )
2018
18
Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. ( 29961863 )
2018
19
Intellectual developmental disorder with cardiac arrhythmia syndrome in a child with compound heterozygous GNB5 variants. ( 29368331 )
2018
20
Sedation in cardiac arrhythmias management. ( 29338549 )
2018
21
Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients. ( 29970732 )
2018
22
Wrapper method for feature selection to classify cardiac arrhythmia. ( 29060691 )
2017
23
Current Interventional and Surgical Management of Congenital Heart Disease: Specific Focus on Valvular Disease and Cardiac Arrhythmias. ( 28302746 )
2017
24
Detection and characterization of intermittent complexity variations in cardiac arrhythmia. ( 28746052 )
2017
25
Alcohol consumption, sinus tachycardia, and cardiac arrhythmias at the Munich Octoberfest: results from the Munich Beer Related Electrocardiogram Workup Study (MunichBREW). ( 28449090 )
2017
26
Impact of Supraventricular Tachyarrhythmia in Patients With Inherited Cardiac Arrhythmia. ( 28951021 )
2017
27
Current state of the art for cardiac arrhythmia gene therapy. ( 28642118 )
2017
28
Phosphorylation of serine96 of histidine-rich calcium-binding protein by the Fam20C kinase functions to prevent cardiac arrhythmia. ( 28784772 )
2017
29
Promoting cardiac arrhythmia care in Africa: a big challenge that begins with data. ( 29309583 )
2017
30
Mechanistic and therapeutic perspectives for cardiac arrhythmias: beyond ion channels. ( 28349303 )
2017
31
Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review. ( 28770640 )
2017
32
Allele-Specific Gene Silencing: Another Step in the Inexorable Advance of Gene Therapy for Cardiac Arrhythmia Management. ( 28819033 )
2017
33
Inhaled nicotine equivalent to cigarette smoking disrupts systemic and uterine hemodynamics and induces cardiac arrhythmia in pregnant rats. ( 29209071 )
2017
34
Cardiac arrhythmia detection using photoplethysmography. ( 29059823 )
2017
35
Sleep Apnea and Nocturnal Cardiac Arrhythmia: Understanding Differences Across Ethnicity. ( 29065964 )
2017
36
Autoantibodies with beta-adrenergic activity from chronic chagasic patients induce cardiac arrhythmias and early afterdepolarization in a drug-induced LQT2 rabbit hearts. ( 28320606 )
2017
37
SK4 K+ channels are therapeutic targets for the treatment of cardiac arrhythmias. ( 28219898 )
2017
38
Severe Hypoglycemia-Induced Fatal Cardiac Arrhythmias are Augmented by Diabetes and Attenuated by Recurrent Hypoglycemia. ( 28887311 )
2017
39
Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. ( 28489458 )
2017
40
Applications of Dynamic Clamp to Cardiac Arrhythmia Research: Role in Drug Target Discovery and Safety Pharmacology Testing. ( 29354069 )
2017
41
Influence of ambient temperature and diurnal temperature range on incidence of cardiac arrhythmias. ( 27568189 )
2017
42
ECG-based 4D-dose reconstruction of cardiac arrhythmia ablation with carbon ion beams: application in a porcine model. ( 28644151 )
2017
43
Echocardiography and cardiac arrhythmias. ( 29203161 )
2017
44
Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de EstimulaciA^n CardA-aca y ElectrofisiologA-a (SOLEACE). ( 29212110 )
2017
45
Numerous Brugada syndrome-associated genetic variants have no effect on J-point elevation, syncope susceptibility, malignant cardiac arrhythmia, and all-cause mortality. ( 27711072 )
2017
46
Role of abnormal repolarization in the mechanism of cardiac arrhythmia. ( 28707396 )
2017
47
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de EstimulaciA^n CardA-aca y ElectrofisiologA-a (SOLEACE). ( 29096024 )
2017
48
Calcium Dynamics and Cardiac Arrhythmia. ( 29230090 )
2017
49
Epac2-Rap1 Signaling Regulates Reactive Oxygen Species Production and Susceptibility to Cardiac Arrhythmias. ( 27649969 )
2017
50
High g-Force Rollercoaster Rides Induce Sinus Tachycardia but No Cardiac Arrhythmias in Healthy Children. ( 27651369 )
2017

Variations for Cardiac Arrhythmia

ClinVar genetic disease variations for Cardiac Arrhythmia:

6
(show top 50) (show all 112)
# Gene Variation Type Significance SNP ID Assembly Location
1 SCN5A NM_198056.2(SCN5A): c.3308C> A (p.Ser1103Tyr) single nucleotide variant risk factor rs7626962 GRCh37 Chromosome 3, 38620907: 38620907
2 SCN5A NM_198056.2(SCN5A): c.3308C> A (p.Ser1103Tyr) single nucleotide variant risk factor rs7626962 GRCh38 Chromosome 3, 38579416: 38579416
3 ANK2 NM_001127493.1(ANK2): c.4400-4039G> A single nucleotide variant Likely pathogenic rs193922637 GRCh37 Chromosome 4, 114277940: 114277940
4 ANK2 NM_001127493.1(ANK2): c.4400-4039G> A single nucleotide variant Likely pathogenic rs193922637 GRCh38 Chromosome 4, 113356784: 113356784
5 RYR2 NM_001035.2(RYR2): c.14314G> A (p.Gly4772Ser) single nucleotide variant Likely pathogenic rs193922622 GRCh37 Chromosome 1, 237972216: 237972216
6 RYR2 NM_001035.2(RYR2): c.14314G> A (p.Gly4772Ser) single nucleotide variant Likely pathogenic rs193922622 GRCh38 Chromosome 1, 237808916: 237808916
7 RYR2 NM_001035.2(RYR2): c.4040T> G (p.Met1347Arg) single nucleotide variant Likely pathogenic rs193922625 GRCh37 Chromosome 1, 237754172: 237754172
8 RYR2 NM_001035.2(RYR2): c.4040T> G (p.Met1347Arg) single nucleotide variant Likely pathogenic rs193922625 GRCh38 Chromosome 1, 237590872: 237590872
9 KCNQ1 NM_000218.2(KCNQ1): c.1343delC (p.Pro448Glnfs) deletion Pathogenic rs397508087 GRCh38 Chromosome 11, 2588804: 2588804
10 KCNQ1 NM_000218.2(KCNQ1): c.1343delC (p.Pro448Glnfs) deletion Pathogenic rs397508087 GRCh37 Chromosome 11, 2610034: 2610034
11 KCNQ1 NM_000218.2(KCNQ1): c.1842_1844delCCA (p.His614del) deletion Pathogenic rs397508101 GRCh37 Chromosome 11, 2869044: 2869046
12 KCNQ1 NM_000218.2(KCNQ1): c.1842_1844delCCA (p.His614del) deletion Pathogenic rs397508101 GRCh38 Chromosome 11, 2847814: 2847816
13 KCNQ1 NM_000218.2(KCNQ1): c.781-14_781-13delGT deletion Benign/Likely benign rs727503103 GRCh37 Chromosome 11, 2594062: 2594063
14 KCNQ1 NM_000218.2(KCNQ1): c.781-14_781-13delGT deletion Benign/Likely benign rs727503103 GRCh38 Chromosome 11, 2572832: 2572833
15 KCNJ8 NM_004982.3(KCNJ8): c.1182G> C (p.Arg394Ser) single nucleotide variant Uncertain significance rs730880120 GRCh37 Chromosome 12, 21918750: 21918750
16 KCNJ8 NM_004982.3(KCNJ8): c.1182G> C (p.Arg394Ser) single nucleotide variant Uncertain significance rs730880120 GRCh38 Chromosome 12, 21765816: 21765816
17 AKAP9 NM_005751.4(AKAP9): c.7034_7036delGAG (p.Arg2345_Glu2346delinsLys) deletion Likely benign rs786205709 GRCh38 Chromosome 7, 92079167: 92079169
18 AKAP9 NM_005751.4(AKAP9): c.7034_7036delGAG (p.Arg2345_Glu2346delinsLys) deletion Likely benign rs786205709 GRCh37 Chromosome 7, 91708481: 91708483
19 AKAP9 NM_005751.4(AKAP9): c.4693-11delT deletion Benign rs786205706 GRCh38 Chromosome 7, 92040663: 92040663
20 AKAP9 NM_005751.4(AKAP9): c.4693-11delT deletion Benign rs786205706 GRCh37 Chromosome 7, 91669977: 91669977
21 CACNB2 NM_000724.3(CACNB2): c.-110391_-110390insG insertion Benign rs769211879 GRCh38 Chromosome 10, 18150879: 18150880
22 CACNB2 NM_000724.3(CACNB2): c.-110391_-110390insG insertion Benign rs769211879 GRCh37 Chromosome 10, 18439808: 18439809
23 RANGRF NM_016492.4(RANGRF): c.52C> T (p.Leu18Phe) single nucleotide variant Uncertain significance rs150856064 GRCh37 Chromosome 17, 8192158: 8192158
24 RANGRF NM_016492.4(RANGRF): c.52C> T (p.Leu18Phe) single nucleotide variant Uncertain significance rs150856064 GRCh38 Chromosome 17, 8288840: 8288840
25 RANGRF NM_016492.4(RANGRF): c.181G> T (p.Glu61Ter) single nucleotide variant Benign rs140704891 GRCh38 Chromosome 17, 8289059: 8289059
26 RANGRF NM_016492.4(RANGRF): c.181G> T (p.Glu61Ter) single nucleotide variant Benign rs140704891 GRCh37 Chromosome 17, 8192377: 8192377
27 ANK2 NM_001148.4(ANK2): c.11683G> C (p.Val3895Leu) single nucleotide variant Uncertain significance rs72556370 GRCh37 Chromosome 4, 114294318: 114294318
28 ANK2 NM_001148.4(ANK2): c.11683G> C (p.Val3895Leu) single nucleotide variant Uncertain significance rs72556370 GRCh38 Chromosome 4, 113373162: 113373162
29 CACNB2 NM_201590.2(CACNB2): c.1044+4_1044+7dupAGTA duplication Conflicting interpretations of pathogenicity rs786205266 GRCh37 Chromosome 10, 18823160: 18823163
30 CACNB2 NM_201590.2(CACNB2): c.1044+4_1044+7dupAGTA duplication Conflicting interpretations of pathogenicity rs786205266 GRCh38 Chromosome 10, 18534231: 18534234
31 KCNH2 NM_000238.3(KCNH2): c.3331-13delG deletion Benign rs794728348 GRCh37 Chromosome 7, 150642615: 150642615
32 KCNH2 NM_000238.3(KCNH2): c.3331-13delG deletion Benign rs794728348 GRCh38 Chromosome 7, 150945527: 150945527
33 KCNH2 NM_000238.3(KCNH2): c.3331-14delT deletion Benign rs794728347 GRCh37 Chromosome 7, 150642616: 150642616
34 KCNH2 NM_000238.3(KCNH2): c.3331-14delT deletion Benign rs794728347 GRCh38 Chromosome 7, 150945528: 150945528
35 KCNH2 NM_000238.3(KCNH2): c.3136delC (p.Gln1046Serfs) deletion Pathogenic rs794728472 GRCh37 Chromosome 7, 150644432: 150644432
36 KCNH2 NM_000238.3(KCNH2): c.3136delC (p.Gln1046Serfs) deletion Pathogenic rs794728472 GRCh38 Chromosome 7, 150947344: 150947344
37 KCNH2 NM_000238.3(KCNH2): c.3105_3112dupGGGCGACG (p.Val1038Glyfs) duplication Pathogenic rs794728470 GRCh38 Chromosome 7, 150947368: 150947375
38 KCNH2 NM_000238.3(KCNH2): c.3105_3112dupGGGCGACG (p.Val1038Glyfs) duplication Pathogenic rs794728470 GRCh37 Chromosome 7, 150644456: 150644463
39 KCNH2 NM_000238.3(KCNH2): c.3104_3107dupGGGG (p.Asp1037Glyfs) duplication Pathogenic rs794728469 GRCh37 Chromosome 7, 150644461: 150644464
40 KCNH2 NM_000238.3(KCNH2): c.3104_3107dupGGGG (p.Asp1037Glyfs) duplication Pathogenic rs794728469 GRCh38 Chromosome 7, 150947373: 150947376
41 KCNH2 NM_000238.3(KCNH2): c.3096_3099dupGCGG (p.Pro1034Alafs) duplication Pathogenic rs794728467 GRCh37 Chromosome 7, 150644469: 150644472
42 KCNH2 NM_000238.3(KCNH2): c.3096_3099dupGCGG (p.Pro1034Alafs) duplication Pathogenic rs794728467 GRCh38 Chromosome 7, 150947381: 150947384
43 KCNH2 NM_000238.3(KCNH2): c.3079C> A (p.Leu1027Ile) single nucleotide variant Likely benign rs794728346 GRCh37 Chromosome 7, 150644489: 150644489
44 KCNH2 NM_000238.3(KCNH2): c.3079C> A (p.Leu1027Ile) single nucleotide variant Likely benign rs794728346 GRCh38 Chromosome 7, 150947401: 150947401
45 KCNH2 NM_000238.3(KCNH2): c.3079dupC (p.Leu1027Profs) duplication Pathogenic rs794728465 GRCh37 Chromosome 7, 150644489: 150644489
46 KCNH2 NM_000238.3(KCNH2): c.3079dupC (p.Leu1027Profs) duplication Pathogenic rs794728465 GRCh38 Chromosome 7, 150947401: 150947401
47 KCNH2 NM_000238.3(KCNH2): c.2966-2_2967dupAGGC duplication Pathogenic rs794728464 GRCh37 Chromosome 7, 150644601: 150644604
48 KCNH2 NM_000238.3(KCNH2): c.2966-2_2967dupAGGC duplication Pathogenic rs794728464 GRCh38 Chromosome 7, 150947513: 150947516
49 KCNH2 NM_000238.3(KCNH2): c.2916_2917dupCC (p.Leu973Profs) duplication Pathogenic rs794728463 GRCh37 Chromosome 7, 150644742: 150644743
50 KCNH2 NM_000238.3(KCNH2): c.2916_2917dupCC (p.Leu973Profs) duplication Pathogenic rs794728463 GRCh38 Chromosome 7, 150947654: 150947655

Expression for Cardiac Arrhythmia

Search GEO for disease gene expression data for Cardiac Arrhythmia.

Pathways for Cardiac Arrhythmia

Pathways related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 CACNA1C GNB5 KCNJ2 KCNQ1 RYR2
2
Show member pathways
12.66 CACNA1C KCNE1 KCNQ1 RYR2 SCN5A
3
Show member pathways
12.34 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
4 12.16 CACNA1C GNB5 KCNE1 KCNE2 KCNH2 KCNJ2
5 11.88 KCNH2 KCNQ1 RYR2 SCN5A
6
Show member pathways
11.87 KCNE2 KCNJ2 KCNQ1
7
Show member pathways
11.8 KCNH2 KCNJ2 KCNQ1
8
Show member pathways
11.51 CACNA1C KCNE1 KCNE2 KCNQ1 RANGRF SCN5A
9 11.07 ANK2 CACNA1C JUP KCNE1 KCNE2 KCNH2
10 10.97 ANK2 SCN5A
11 10.78 KCNE1 KCNJ2 KCNQ1

GO Terms for Cardiac Arrhythmia

Cellular components related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosome GO:0005764 9.73 ANK2 KCNE1 KCNE2 KCNQ1
2 sarcolemma GO:0042383 9.58 ANK2 RYR2 SCN5A
3 voltage-gated potassium channel complex GO:0008076 9.55 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
4 T-tubule GO:0030315 9.5 ANK2 KCNJ2 SCN5A
5 smooth endoplasmic reticulum GO:0005790 9.46 KCNJ2 RYR2
6 intercalated disc GO:0014704 9.35 ANK2 JUP KCNJ2 RANGRF SCN5A
7 Z disc GO:0030018 9.1 ANK2 CACNA1C JUP KCNE1 RYR2 SCN5A
8 membrane GO:0016020 10.15 ANK2 CACNA1C GNB5 JUP KCNE1 KCNE2
9 plasma membrane GO:0005886 10.03 ANK2 CACNA1C GNB5 JUP KCNE1 KCNE2

Biological processes related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.98 CACNA1C KCNQ1 RYR2 SCN5A
2 regulation of ion transmembrane transport GO:0034765 9.98 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
3 potassium ion transport GO:0006813 9.97 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
4 potassium ion transmembrane transport GO:0071805 9.96 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
5 cardiac muscle contraction GO:0060048 9.88 KCNH2 KCNQ1 RYR2 SCN5A
6 regulation of heart rate GO:0002027 9.85 ANK2 RANGRF RYR2 SCN5A
7 cellular response to drug GO:0035690 9.84 KCNE2 KCNH2 KCNQ1
8 positive regulation of potassium ion transmembrane transport GO:1901381 9.83 KCNE1 KCNH2 KCNJ2 KCNQ1
9 membrane repolarization GO:0086009 9.81 KCNE1 KCNE2 KCNH2 KCNQ1
10 membrane depolarization during action potential GO:0086010 9.8 CACNA1C KCNH2 SCN5A
11 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.8 KCNE1 KCNH2 KCNJ2 KCNQ1
12 cardiac muscle cell action potential involved in contraction GO:0086002 9.8 CACNA1C KCNE1 KCNE2 KCNJ2 SCN5A
13 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.79 ANK2 CACNA1C RYR2
14 regulation of potassium ion transmembrane transport GO:1901379 9.79 KCNE1 KCNE2 KCNH2
15 regulation of cardiac muscle cell contraction GO:0086004 9.78 ANK2 KCNJ2 SCN5A
16 potassium ion export GO:0071435 9.78 KCNE1 KCNE2 KCNH2 KCNQ1
17 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.77 CACNA1C KCNJ2 SCN5A
18 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.77 CACNA1C JUP RYR2
19 regulation of membrane repolarization GO:0060306 9.77 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
20 atrial cardiac muscle cell action potential GO:0086014 9.76 ANK2 KCNQ1 SCN5A
21 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.76 KCNE1 KCNE2 KCNH2 KCNQ1
22 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.73 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
23 membrane repolarization during action potential GO:0086011 9.72 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
24 potassium ion import GO:0010107 9.7 KCNE2 KCNJ2
25 regulation of cardiac muscle contraction GO:0055117 9.7 ANK2 RYR2
26 positive regulation of heart rate GO:0010460 9.7 KCNQ1 RYR2
27 cardiac conduction GO:0061337 9.7 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
28 calcium ion transport into cytosol GO:0060402 9.69 CACNA1C RYR2
29 cellular response to epinephrine stimulus GO:0071872 9.69 KCNQ1 RYR2
30 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.69 CACNA1C RYR2
31 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.68 KCNE1 KCNE2
32 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.68 ANK2 RYR2
33 regulation of sodium ion transmembrane transport GO:1902305 9.67 RANGRF SCN5A
34 regulation of delayed rectifier potassium channel activity GO:1902259 9.67 KCNE1 KCNE2
35 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.66 KCNQ1 SCN5A
36 SA node cell action potential GO:0086015 9.66 ANK2 SCN5A
37 membrane depolarization during AV node cell action potential GO:0086045 9.65 CACNA1C SCN5A
38 membrane depolarization during SA node cell action potential GO:0086046 9.65 ANK2 SCN5A
39 sarcoplasmic reticulum calcium ion transport GO:0070296 9.65 ANK2 RYR2
40 potassium ion export across plasma membrane GO:0097623 9.64 KCNH2 KCNQ1
41 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.64 CACNA1C SCN5A
42 regulation of atrial cardiac muscle cell action potential GO:0098910 9.63 ANK2 RYR2
43 regulation of SA node cell action potential GO:0098907 9.63 ANK2 RYR2
44 regulation of heart rate by cardiac conduction GO:0086091 9.61 ANK2 CACNA1C JUP KCNE1 KCNE2 KCNH2
45 ventricular cardiac muscle cell action potential GO:0086005 9.17 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 RYR2
46 ion transport GO:0006811 10.14 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
47 transmembrane transport GO:0055085 10.08 CACNA1C KCNH2 KCNQ1 RYR2 SCN5A

Molecular functions related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.84 ANK2 JUP RYR2 SCN5A
2 calmodulin binding GO:0005516 9.78 CACNA1C KCNQ1 RYR2 SCN5A
3 ion channel activity GO:0005216 9.76 CACNA1C KCNH2 RYR2 SCN5A
4 voltage-gated ion channel activity GO:0005244 9.73 CACNA1C KCNE2 KCNH2 KCNJ2 KCNQ1 SCN5A
5 potassium channel activity GO:0005267 9.71 KCNE1 KCNE2 KCNH2 KCNQ1
6 scaffold protein binding GO:0097110 9.67 KCNH2 KCNQ1 SCN5A
7 voltage-gated potassium channel activity GO:0005249 9.67 KCNE1 KCNE2 KCNH2 KCNQ1
8 ion channel binding GO:0044325 9.63 ANK2 KCNE2 KCNQ1 RANGRF RYR2 SCN5A
9 delayed rectifier potassium channel activity GO:0005251 9.62 KCNE1 KCNE2 KCNH2 KCNQ1
10 inward rectifier potassium channel activity GO:0005242 9.61 KCNE2 KCNH2 KCNJ2
11 potassium channel regulator activity GO:0015459 9.55 KCNE1 KCNE2
12 protein kinase A regulatory subunit binding GO:0034237 9.52 KCNQ1 RYR2
13 protein kinase A catalytic subunit binding GO:0034236 9.51 KCNQ1 RYR2
14 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.26 KCNE1 KCNE2 KCNH2 KCNQ1
15 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 8.92 KCNE1 KCNH2 KCNJ2 KCNQ1

Sources for Cardiac Arrhythmia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....